Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1978 1
1992 1
1998 3
1999 1
2000 2
2001 8
2002 1
2003 1
2004 3
2005 3
2006 1
2007 5
2008 6
2009 3
2010 4
2011 10
2012 5
2013 9
2014 14
2015 17
2016 22
2017 19
2018 16
2019 22
2020 35
2021 41
2022 31
2023 29
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Frailty syndrome and risks for falling in the elderly community.
Taguchi CK, Menezes PL, Melo ACS, Santana LS, Conceição WRS, Souza GF, Araújo BCL, Silva ARD. Taguchi CK, et al. Among authors: melo acs. Codas. 2022 Aug 8;34(6):e20210025. doi: 10.1590/2317-1782/20212021025pt. eCollection 2022. Codas. 2022. PMID: 35946721 Free PMC article.
World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease.
Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, Chen MH, Choi MG, Melo AC, Fock KM, Ford A, Hongo M, Khan A, Lazebnik L, Lindberg G, Lizarzabal M, Myint T, Moraes-Filho JP, Salis G, Lin JT, Vaidya R, Abdo A, LeMair A; Review Team:. Hunt R, et al. Among authors: melo ac. J Clin Gastroenterol. 2017 Jul;51(6):467-478. doi: 10.1097/MCG.0000000000000854. J Clin Gastroenterol. 2017. PMID: 28591069 No abstract available.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Kristeleit R, et al. Among authors: de melo ac. Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14. Lancet Oncol. 2022. PMID: 35298906 Clinical Trial.
Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries.
Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Silva CPE, Kennedy-Feitosa E, Melo AC, Cattani-Cavalieri I, Porto LC, Valenca SS. Bezerra FS, et al. Among authors: melo ac. Antioxidants (Basel). 2023 Feb 21;12(3):548. doi: 10.3390/antiox12030548. Antioxidants (Basel). 2023. PMID: 36978796 Free PMC article. Review.
Molecular landscape of Hereditary Melanoma.
Ribeiro Moura Brasil Arnaut J, Dos Santos Guimarães I, Evangelista Dos Santos AC, de Moraes Lino da Silva F, Machado JR, de Melo AC. Ribeiro Moura Brasil Arnaut J, et al. Among authors: de melo ac. Crit Rev Oncol Hematol. 2021 Aug;164:103425. doi: 10.1016/j.critrevonc.2021.103425. Epub 2021 Jul 7. Crit Rev Oncol Hematol. 2021. PMID: 34245855 Review.
An Update on Mucosal Melanoma: Future Directions.
Goldemberg DC, Thuler LCS, de Melo AC. Goldemberg DC, et al. Among authors: de melo ac. Acta Dermatovenerol Croat. 2019 Mar;27(1):11-15. Acta Dermatovenerol Croat. 2019. PMID: 31032785 Review.
Implementation of a pharmacogenomic program in a Brazilian public institution.
Suarez-Kurtz G, Kovaleski G, Elias AB, Motta V, Wolch K, Emerenciano M, Mansur MB, Palladino AM, Accioly MT, Ferreira M, Gonçalves AA, de Melo AC. Suarez-Kurtz G, et al. Among authors: de melo ac. Pharmacogenomics. 2020 Jun;21(8):549-557. doi: 10.2217/pgs-2020-0016. Epub 2020 May 7. Pharmacogenomics. 2020. PMID: 32378980 Review.
281 results